Oxford Asset Management’s Lineage Cell Therapeutics LCTX Stock Holding History

Oxford Asset Management’s Portfolio LCTX Stock Details LCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-39,842	Closed	-$35K	–	792
2019 Q4	$35K	Sell	39,842 -110,822	-74%	-$92.3K	﹤0.01%	1679
2019 Q3	$148K	Buy	150,664 +17,851	+13%	+$18.5K	﹤0.01%	1603
2019 Q2	$146K	Sell	132,813 -28,465	-18%	-$32.8K	﹤0.01%	1589
2019 Q1	$211K	Buy	161,278 +45,869	+40%	+$57.1K	﹤0.01%	1498
2018 Q4	$105K	Buy	+115,409	New	+$177K	﹤0.01%	1645
2017 Q2	–	Sell	-16,822	Closed	-$51K	–	1595
2017 Q1	$51K	Buy	+16,822	New	+$47.8K	﹤0.01%	1374
2015 Q3	–	Sell	-140,390	Closed	-$411K	–	678
2015 Q2	$411K	Buy	+140,390	New	+$544K	0.01%	547

Other funds holding LCTX

Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return

PGP

Prescott General Partners Boca Raton, Florida $1.96B AUM 58.65% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

NFC

Northeast Financial Consultants Westport, Connecticut $2.45B AUM 15.14% 1-Year Est. Return

Oxford Asset Management's LCTX Position: Q1 2020 in Review

Oxford Asset Management sold out of Lineage Cell Therapeutics (LCTX) in Q1 2020, closing a stake of 39,842 shares — an estimated $35K sold.

Oxford Asset Management first reported a position in LCTX in Q2 2015 and held it in 7 quarters. The position peaked at $411K in Q2 2015. 97 funds tracked by Wall St. Rank hold LCTX as of Q1 2020.

Oxford Asset Management reported no remaining Lineage Cell Therapeutics position as of Q1 2020 after selling out during the quarter.
Oxford Asset Management sold 39,842 Lineage Cell Therapeutics shares in Q1 2020, an estimated $35K.
Oxford Asset Management first reported a position in Lineage Cell Therapeutics in Q2 2015 and held it in 7 quarters.
Oxford Asset Management's Lineage Cell Therapeutics position peaked at $411K in Q2 2015.
97 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q1 2020.

Based on Oxford Asset Management's 13F filing for Q1 2020, filed 15 May 2020.